SCHEMBL980667

SCHEMBL980667

COCCn1ncc(OC)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 3/20 0.39
MAPK1 P28482 1/20 0.39
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2C P18825 1/20 0.38
DRD4 P21917 1/20 0.38
HRH2 P25021 1/20 0.38
HTR1B P28222 1/20 0.38
HTR2A P28223 1/20 0.38
HTR7 P34969 1/20 0.38
ADRA1A P35348 1/20 0.38
HRH1 P35367 1/20 0.38
ADRA1B P35368 1/20 0.38
HTR2B P41595 1/20 0.38
SIGMAR1 Q99720 1/20 0.38
CLK4 Q9HAZ1 3/20 0.36
LMNA P02545 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24184142 0.81 ALDH1A1 (0.41) CYP1A2ALDH1A1CYP3A4MAPK1CLK4
SCHEMBL980682 0.81 PDE1A (0.43) CYP3A4HTR1AADRA2ADRD2ADRA2C
SCHEMBL983515 0.80 ALDH1A1 (0.40) CYP1A2ALDH1A1CYP3A4CLK4MEN1
SCHEMBL979263 0.74 HTR3A (0.38) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL1550906 0.74 NPBWR1 (0.59) MEN1KMT2ANPBWR1SMN1; SMN2
SCHEMBL979238 0.69 TAS2R8 (0.32) CYP1A2ALDH1A1CYP3A4MAPK1CLK4
SCHEMBL981042 0.69 LRRK2 (0.34) CYP1A2ALDH1A1CYP3A4MAPK1HTR2A
Hydrochloric Acid SCHEMBL31078258 0.68 IDO1 (0.43) CYP1A2ALDH1A1CYP3A4MAPK1CLK4
SCHEMBL981321 0.68 RAB9A (0.48) ALDH1A1HSD17B10RAB9AKDM4ENPC1
SCHEMBL978628 0.67 HTT (0.53) CYP1A2ALDH1A1CYP3A4MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2456765-B1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2013-05-01 EP disclosed
US-8334287-B2 Imidazoles HOFFMANN-LA ROCHE INC. (US) 2012-12-18 US disclosed
EP-2456765-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-05-30 EP disclosed
WO-2011006910-A1 IMIDAZOLE DERIVATIVES AS MGLUR5 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 WO disclosed
US-20110015202-A1 IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015202-A1 IMIDAZOLES GRM5, GRM1, GRIK5 CYP1A2 1068/4885ALDH1A1 1642/4885CYP3A4 1026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.